Isosorbide dinitrate/hydralazine is a drug combination specifically indicated for African Americans with congestive heart failure. It is a combination of hydralazine (an antihypertensive) and isosorbide dinitrate (a vasodilator). It is the first race-based prescription drug in the United States. The combination preparation is marketed in the United States by Nitromed under the trade name BiDil.
Originally rejected by the Food and Drug Administration (FDA) in 1997, the combination preparation was approved by the FDA in June 2005 for African American-use only based on the results of a study by Taylor et al. (2004). It was already known that African Americans with congestive heart failure (CHF) respond less effectively to conventional CHF treatments (particularly ACE inhibitors) than Caucausians. (Exner, 2001) The study by Taylor et al. demonstrated that isosorbide dinitrate with hydralazine reduced mortality by 43%, reduced hospitalizations by 33%, and quality of life markers in African Americans patients with CHF.
Some argue that because the combination preparation is comprised of two generically-available drugs, widely available at a small fraction of the cost, BiDil is a marketing breakthrough, rather than a medical one. Others argue that the combination reduces the "pill burden" for patients, which improves compliance and therefore the medical outcome.
More on [ Isosorbide dinitrate/hydralazine ]

BiDil - Listing for FDA approved drug therapies archives from CenterWatch. (isosorbide dinitrate/hydralazine hydrochloride)
Meta Description: [ Listing for BiDil (isosorbide dinitrate/hydralazine hydrochloride) in FDA Approved Drug Therapies Archives from CenterWatch Clinical Trials Listing Service ]
BiDil - Information on the drug proven to be an effective treatment for African Americans with heart failure, cardiovascular disease, and/or diabetes.
Meta Description: [ BiDil was approved by the FDA based the results from the African American Heart Failure Trial (A-HeFT). The drug, which combines isosorbide dinitrate and hydralazine hydrochloride, was proven to be an effective treatment for African Americans with heart failure, cardiovascular disease, and/or dia... ]
| Quality Stocks Daily Video 10/24/2008 | |